The HBV Refresher: Screen, Diagnose, Treat

Faculty

Kris V. Kowdley, MD, FACP, FACG, AGAF, FAASLD
Moderator
Su H. Wang, MD, MPH, FACP
Medical Director, Viral Hepatitis Programs and Center for Asian Health
Cooperman Barnabas Medical Center, RJWBarnabas Health
Livingston, NJ
Su H. Wang, MD, MPH, FACP

Su Wang, MD, MPH, FACP is the Medical Director of Viral Hepatitis Programs and the Center for Asian Health at Cooperman Barnabas Medical Center and a member of the RWJBarnabas Health Medical Group. She is Past President of the World Hepatitis Alliance, a non-governmental organization (NGO) committed to viral hepatitis elimination.

Dr. Wang is an internist and has served as primary investigator for a number of viral hepatitis screening and linkage-to-care grants sponsored by the U.S. Centers for Disease Control and Prevention (CDC) and other funders. She has led primary care-based hepatitis B and C programs, community outreach efforts, patient-based advocacy, and community-based research initiatives.

Dr. Wang has served on a number of World Health Organization (WHO) guideline development committees producing “Prevention of Mother-to-Child Transmission of Hepatitis B Virus: Guidelines on Antiviral Prophylaxis in Pregnancy” and “Interim Guidance for Country Validation of Viral Hepatitis Elimination.” She is a member of the American Association for the Study of Liver Diseases (AASLD) and serves on the steering committee for the HBV Special Interest Group and the Viral Hepatitis Elimination Taskforce, and is on the Patient Advisory Group.

She received her medical degree from the University of Miami and her Masters of Public Health from Johns Hopkins School of Public Health. Dr. Wang completed a combined Internal Medicine and Pediatric residency at Georgetown University Hospital and then served as an Epidemic Intelligence Service officer for the CDC at the U.S. Food and Drug Administration (FDA). She was previously the Director of Hepatitis Programs at the Charles B. Wang Community Health Center in New York City.

Statement of Need

Despite updated guidance from the American Association for the Study of Liver Diseases (AASLD) on the prevention, diagnosis, and treatment of chronic hepatitis B virus (HBV), early detection and implementation of effective treatment remains a challenge.

The first episode of this CMEOcast series on community-based efforts to improve screening and treatment of HBV will guide primary care clinicians through optimal strategies to screen for HBV in at-risk patients and utilize serological test results to drive guideline-directed care.

Learning Objectives

At the end of this CME/CE activity, participants should be able to implement routine screening protocols for HBV in the primary care setting and utilize results to drive guideline-directed care


The following learning objectives pertain only to those requesting CNE or CPE credit: Summarize routine screening protocols for HBV in the primary care setting

Financial Support

Supported by an educational grant from Gilead Sciences, Inc.

Target Audience

Primary care physicians, OB/GYNs, ED physicians, PAs, nurse practitioners, and pharmacists.

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit  from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.


Dr. Kowdley reports that he receives research support from Conatus Pharmaceuticals Inc.; CymaBay Therapeutics; Enanta Pharmaceuticals, Inc.; Genfit; Gilead Sciences, Inc.; GlaxoSmithKline; HighTide Therapeutics Inc.; Intercept Pharmaceuticals, Inc.; and Zydus Pharmaceuticals, Inc. He is on the advisory committee for Assembly Biosciences, Inc.; Blade Therapeutics; Boehringer Ingelheim; Merck & Co., Inc.; and Roche. He is on the speakers bureau for AbbVie Inc.; Gilead Sciences, Inc.; and Intercept Pharmaceuticals, Inc.


Dr. Wang reports that she receives grants from Gilead Sciences, Inc.


Kashemi Rorie, PhD (planning committee) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.


Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

 


NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-167-H01-P.

 

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

 

PD-035-113020-47

The HBV Refresher: Screen, Diagnose, Treat
Event Date: 11/30/2020